Mike Fraser | Head of EMEA Region
Novartis Gene Therapies

Mike Fraser, Head of EMEA Region, Novartis Gene Therapies

Mike Fraser is General Manager of Europe, Middle East and Africa for Novartis Gene Therapies. In this role, Mike is leading a team that will introduce innovative Gene Therapies to the market to help babies and their families who suffer from rare neuromuscular diseases. Previously, Mike led Sandoz? newly formed function as Vice President of Strategy, Innovation and Analytics. In this role, Mike led a team charged with bringing together the critical future-focused functions that would shape Sandoz? future direction as a company, identified new future opportunities at an early stage, and nurtured disruptive business opportunities. An expert in digital innovation, Mike also chaired the commercialization partnership that was responsible for launching the first prescription digital therapeutic to the US market. Mike joined Sandoz in July 2018. Mike has been with Novartis since 1994 and has experience in both Country and Global environments. He has worked on all stages of the products? life cycle from early development through launch, as well as managing successful in-line brands in multiple therapeutic areas. Mike has led teams in PLS (Product Lifecycle Services), Cell and Gene Therapies Unit and before that, Mike was the Head of the New Products team for the US Pharma organization.


Day 1: Wednesday 19th May 2021 - Cell Therapy @ 11:30

Keynote panel discussion: State of the industry panel

  • How have events over the last 12 months affected the industry? Maintaining
  • Where is the ATMP field headed?
  • Who is making the best progress?
  • What is new on the market?
  • The Next Wave: moving beyond CAR-T and Gene Therapy, what’s next?

Day 2: Thursday 20th May 2021 - Gene Therapy @ 13:00

Keynote panel discussion: The next generation of gene therapy

·Latest technology updates·Scientific nuances, new indications + clinical design

Day 3: Friday 21st May 2021 - Commercialisation, Pricing & Access @ 13:00

Keynote panel discussion: Finding the right framework for reimbursement and market access for cell and gene therapies

·Europe vs USA vs ROW?·Reimbursement strategies·What’s driving the decision makers at country and national level?
last published: 10/May/21 08:45 GMT

back to speakers